IF Alpha?

My biggest concern last fall was, "what if Bernie gets into office?" This fear was driven partially by the fact that the market would...

It’s Definitely a Beer Market

Sometimes a typo can hit the sweet spot, right? When I got the text that we're entering a beer market...well, let's just say that...

INMB: INmune Bio Earnings Call Transcript

INmune Bio, Inc. Fourth Quarter and Full Year 2019 Earnings Call March 11, 2020, 11 AM  Presenters Landon Baretto, Moderator Raymond J. Tesi, MD, CEO David J....

INMB: Interview with Dr. CJ Barnum, Director of Neuroscience

INmune Bio (INMB) is developing a drug targeting the innate immune system and, specifically, its role in the development of chronic inflammation as humans...

Thoughts From Last Week

This feels like a very strange time in the market. Usually markets overreact to news. Violent swings to extreme levels are the common occurrence...

Thoughts From The Last Week…

Lots going on in Tailwinds' universe recently. Here I recap conversations and observations from the prior week's trading... This screen shot says it all...if Druck...

INmune Webinar Transcript: Bench to Bedside

R.J.: So, hello everybody, I'm R.J. Tesi. I'm the CEO and Acting Chief Medical Officer of Inmune Bio, and today I'll be hosting...

INmune Bio, Inc. Awarded $500,000 Grant for Development of Novel Treatment to Reprogram Innate...

Tailwinds' Take: yet another disease where neuro-inflammation plays a role. The breadth of potential treatments for this product is staggering. LA JOLLA, Calif. , Feb....

Slogging Through Winter

I was skiing outside Seattle last weekend. Steven's Pass ski resort, to be precise. They have gotten a lot of snow up there this...

Wasn’t That An Amazing Sunset?

On Thursday this week, as we finished dinner I looked out the window and the sky was on fire. It was quite possibly the...

INmune’s Efforts in Alzheimer’s…Low Risk to Phase 1b Success???

In December of 2019, INmune Bio (INMB) commenced dosing of humans in a Phase 1b trial of XPro1595 (XPro), a drug targeting Alzheimer’s Disease....

What to Expect When Everyone’s Expecting (An Up Market)

What a difference a year makes. Christmas 2018 marked a time of anguish for investors. The market was in the toilet and, for us...

Nmune Bio, Inc. Announces Data on its Lead Compound Which Highlights The Potential to...

Tailwinds' Take: more solid data that should translate very well into humans. Remember, INmune has an ongoing Phase 1b trial in Alzheimer's Disease right...

Visions of 2020

This last week was actually a very good week for the Tailwinds' portfolio. Despite the overall quiet of a holiday week (or maybe because...

INmune Bio Announces Final Phase I Clinical Data for its Soluble TNF Inhibitor, INB03,...

Tailwinds' Take: this is a very positive step for this platform. Next steps here are to start a Phase IIa open-label trial next summer,...

Introducing INmune Bio

We are initiating coverage today on INmune Bio (Nasdaq: INMB). According to the Company, INmune (INMB) is “Reprogramming the Innate Immune System for the...

INmune Bio, Inc. Announces First Alzheimer’s Disease Patient Dosed in XPro1595 Study

Tailwinds' Take: this trial looks poised for success as XPro1595 is known to be safe and reduce inflammation, the endpoints for this trial design.  LA...

INmune Bio Inc. to Discuss Potential New Alzheimer’s Disease Treatments in CTAD Pre-Conference Webinar

LA JOLLA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- -- INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s...

Deep Fried Turkey

Those who know me well are well aware that Wednesdays are my favorite night of the week. That's the night I go out mountain...

INmune Bio, Inc. Strengthens Board of Directors with Appointment of Veteran Finance Executive Marcia...

LA JOLLA, Calif., Nov. 19, 2019 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB), an immunology company developing treatments that harness the patient’s innate immune...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.